Cassandra M Hirsch

List of Publications by Year
in descending order

35 papers	1,004 citations	623734 14 h-index	501196 28 g-index
36 all docs	36 docs citations	36 times ranked	1735 citing authors

#	Article	IF	Citations
1	Dynamics of clonal evolution in myelodysplastic syndromes. Nature Genetics, 2017, 49, 204-212.	21.4	348
2	Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 3737-3746.	1.6	90
3	Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). Leukemia and Lymphoma, 2018, 59, 416-422.	1.3	72
4	Rational management approach to pure red cell aplasia. Haematologica, 2018, 103, 221-230.	3.5	57
5	Consequences of mutant TET2 on clonality and subclonal hierarchy. Leukemia, 2018, 32, 1751-1761.	7.2	54
6	Origins of myelodysplastic syndromes after aplastic anemia. Blood, 2017, 130, 1953-1957.	1.4	50
7	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. Blood Cancer Journal, 2018, 8, 4.	6.2	43
8	Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes. Blood, 2018, 132, 2309-2313.	1.4	38
9	Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia. Blood Advances, 2019, 3, 339-349.	5.2	36
10	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Advances, 2019, 3, 4228-4237.	5.2	34
11	Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. Leukemia, 2020, 34, 957-962.	7.2	32
12	Molecular pathogenesis of disease progression in MLL-rearranged AML. Leukemia, 2019, 33, 612-624.	7.2	26
13	Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia. Nature Communications, 2022, 13, 1981.	12.8	23
14	Molecular features of early onset adult myelodysplastic syndrome. Haematologica, 2017, 102, 1028-1034.	3.5	20
15	BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes. Leukemia and Lymphoma, 2019, 60, 1587-1590.	1.3	16
16	Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML. Oncotarget, 2018, 9, 2050-2057.	1.8	16
17	Clonal PIGA mosaicism and dynamics in paroxysmal nocturnal hemoglobinuria. Leukemia, 2018, 32, 2507-2511.	7.2	11
18	Distinctive and common features of moderate aplastic anaemia. British Journal of Haematology, 2020, 189, 967-975.	2.5	10

#	Article	IF	Citations
19	A myeloid tumor suppressor role for NOL3. Journal of Experimental Medicine, 2017, 214, 753-771.	8.5	8
20	Reduced red blood cell surface level of Factor H as a mechanism underlying paroxysmal nocturnal hemoglobinuria. Leukemia, 2021, 35, 1176-1187.	7.2	4
21	Impact of Eltrombopag on Expansion of Clones with Somatic Mutations in Refractory Aplastic Anemia. Blood, 2015, 126, 300-300.	1.4	3
22	5-formylcytosine and 5-hydroxymethyluracil as surrogate markers of TET2 and SF3B1 mutations in myelodysplastic syndrome, respectively. Haematologica, 2020, 105, e213-e215.	3.5	2
23	Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms. Blood, 2019, 134, 4238-4238.	1.4	2
24	Molecular and Immunophenotypic Characteristics of Adult Acute Leukemias of Ambiguous Lineage. Blood, 2016, 128, 1659-1659.	1.4	2
25	Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes. Blood, 2016, 128, 4301-4301.	1.4	2
26	Extent and Clinical Implications of Subclonal Diversity in Paroxysmal Nocturnal Hemoglobinuria. Blood, 2017, 130, 779-779.	1.4	2
27	PHF6 - Somatic Mutations and Their Role in Pathophysiology of MDS and AML. Blood, 2015, 126, 1259-1259.	1.4	1
28	Subcutaneous Low Dose Alemtuzumab: Role As a Salvage Therapy in Immune -Mediated Marrow Failure Conditions. Blood, 2016, 128, 1505-1505.	1.4	1
29	BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden. Blood, 2018, 132, 4352-4352.	1.4	1
30	Determinants of Phenotypic Commitment and Clonal Progression--Conclusions from the Study of Clonal Architecture in CMML. Blood, 2015, 126, 2848-2848.	1.4	0
31	Network-Based Analysis of Exome Sequencing Mutations Identifies Molecular Subtypes of Myelodysplastic Syndromes. Blood, 2015, 126, 611-611.	1.4	0
32	BCOR and BCORL1 mutations in Myelodysplastic Syndromes (MDS): Clonal Architecture and Impact on Outcomes. Blood, 2016, 128, 4293-4293.	1.4	0
33	Heterozygous CTC1 Variants in Acquired Bone Marrow Failure. Blood, 2018, 132, 3866-3866.	1.4	0
34	Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS. Blood, 2018, 132, 3074-3074.	1.4	0
35	Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia. Blood, 2018, 132, 1527-1527.	1.4	0